One of the greatest challenges in oncology is represented by those cancers that do not respond to conventional drug treatments. ViroStatics discovers and develops novel, selective, host cell kinase targeted inhibitors for a multifaceted treatment of most aggressive cancers with high unmet medical need.
Consistent with its mechanism of action, the lead compound VS2-370 is more active against CDK4/6/9 dependent tumors, such as pancreatic cancer, aggressive lymphomas, leukemias, lung cancer and breast cancer.
ViroStatics’ clinical candidate VS2-370, in advanced preclinical development, displays a good druggability profile and some unique features:
- Selectively targets two different kinase pathways that act synergistically against cancers
- Active against aggressive cancers
- Inhibits tumor cell proliferation and induces selective tumor killing
- Greater potency and better toxicity profile than CDK4/6 and CDK9 inhibitors
- Therapeutically relevant activity against CDK4/6 inhibitors-resistant cancers
- Promising combination profile with drugs against pancreatic cancer and haemato-oncology cancers
- Exhibit a promising safety profile, have good oral bioavailability and PK/PD profile in tumor models
- Human clinical trials to be started by 2019; strategy for clinical pathway to Proof of Concept elucidated
- New chemical entities – patent protected beyond 2030